BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32353632)

  • 1. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model.
    Stockhammer P; Ho CSL; Hegedus L; Lotz G; Molnár E; Bankfalvi A; Herold T; Kalbourtzis S; Ploenes T; Eberhardt WEE; Schuler M; Aigner C; Schramm A; Hegedus B
    Lung Cancer; 2020 Jun; 144():20-29. PubMed ID: 32353632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
    Itchins M; Lau B; Hudson AL; Westman H; Xia CY; Hayes SA; Howell VM; Rodriguez M; Cooper WA; Wei H; Buckland M; Li BT; Li M; Rathi V; Fox SB; Gill AJ; Clarke SJ; Boyer MJ; Pavlakis N
    Oncologist; 2020 Aug; 25(8):641-649. PubMed ID: 32558067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Sheinson D; Wong WB; Wu N; Mansfield AS
    Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
    J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
    Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
    Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Shi R; Filho SNM; Li M; Fares A; Weiss J; Pham NA; Ludkovski O; Raghavan V; Li Q; Ravi D; Cabanero M; Moghal N; Leighl NB; Bradbury P; Sacher A; Shepherd FA; Yasufuku K; Tsao MS; Liu G
    Lung Cancer; 2020 Aug; 146():78-85. PubMed ID: 32521388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
    Song P; Zhang X; Yang D; Wang H; Si X; Zhang L
    Thorac Cancer; 2020 May; 11(5):1216-1223. PubMed ID: 32181989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
    Fukuda K; Takeuchi S; Arai S; Katayama R; Nanjo S; Tanimoto A; Nishiyama A; Nakagawa T; Taniguchi H; Suzuki T; Yamada T; Nishihara H; Ninomiya H; Ishikawa Y; Baba S; Takeuchi K; Horiike A; Yanagitani N; Nishio M; Yano S
    Cancer Res; 2019 Apr; 79(7):1658-1670. PubMed ID: 30737231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
    Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
    Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Moskovitz M; Dudnik E; Shamai S; Rotenberg Y; Popovich-Hadari N; Wollner M; Zer A; Gottfried M; Mishaeli M; Rosenberg SK; Onn A; Merimsky O; Urban D; Peled N; Maimon N; Bar J
    Oncologist; 2022 Feb; 27(1):e76-e84. PubMed ID: 35305096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Cell-Free DNA for the Detection of
    McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
    Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
    [No Abstract]   [Full Text] [Related]  

  • 18. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.